 
        
        
        
                货号:A173012
                
                同义名:
                    
                        
                            2-羟基-4-甲氧基苯乙酮
                            
                             / 2'-Hydroxy-4'-methoxyacetophenone; Peonol
                            
                        
                    
                
                
                
                    
                     
                    
                     
                
            
Paeonol是一种天然的单胺氧化酶(MAO)抑制剂,对MAO-A和MAO-B的IC50值分别为54.6 μM和42.5 μM。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | MAO ↓ ↑ | MAO-A ↓ ↑ | MAO-B ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sennoside A | ++ MAO, IC50: 17 μM | 98%+ | |||||||||||||||||
| Glycyrrhizic acid | ++++ MAO, IC50: 0.16 μM | 80% HPLC | |||||||||||||||||
| Rasagiline | ++++ MAO-A, IC50: 412 nM | ++++ MAO-B, IC50: 4.43 nM | 97% | ||||||||||||||||
| Isatin | ++ MAO, IC50: 15 μM | + MAO-A, IC50: 58 μM | ++ MAO-B, IC50: 14 μM | 98% | |||||||||||||||
| Paeonol | + MAO-A, IC50: 54.6 μM | + MAO-B, IC50: 42.5 μM | 98% | ||||||||||||||||
| Tranylcypromine HCl | +++ MAO-A, IC50: 11.5 μM | +++ MAO-B, IC50: 7 μM | 97% | ||||||||||||||||
| Moclobemide | +++ MAO-A (5-HT), IC50: 6.1 μM | 99%+ | |||||||||||||||||
| Pargyline HCl | ++ MAO-A, Ki: 13 μM | +++ MAO-B, Ki: 0.5 μM | 99%+ | ||||||||||||||||
| Safinamide | ++++ MAO-B, IC50: 98 nM | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | Monoamine oxidase (MAO) is an important enzyme in the metabolism of a wide range of endogenous monoamine neurotrasmitters such as noradrenaline, dopamine, and serotonin (5-HT), and also catalyzes as well the removal of exogenous amines. Paeonol, originated from the traditional Chinese medicine, is a naturally occuring MAO inhibitor with IC50 values of 54.6 μM and 42.5 μM for MAO-A and MAO-B, respectively[7]. Paeonol dose- and time- dependently induced not only antiproliferation activity and apoptosis but also autophagy via blocking the Akt/mTOR pathway in A2780 and SKOV3 cells. In addition, combination treatment with Paeonol and an autophagy inhibitor (3-methyladenine and hydroxychloroquine) showed significant synergetic effects on inhibiting cell viability and promoting apoptosis in vitro and in the A2780 xenograft model, without severe side effects[8]. Paeonol at 50 and 100μM prevented IL-1β-induced inflammatory response by inhibiting numerous factors of osteoarthritis(OA), including IL-6, TNF-a, NOX2, PTGS2, NUCB2/nesfatin-1, ICAM-1, VCAM-1, MMP-3/13, degradation of type II collagen, and NF-kB activation through the rescue of IkBa in human primary chondrocytes[9]. | 
| Concentration | Treated Time | Description | References | |
| HCT116 cells | 7.8125, 15.625, 31.25, 62.5, 125, 250 and 500 µg/ml | 12, 24, 48 and 72 hours | To assess the inhibitory effect of Paeonol on HCT116 cell viability, the results showed that Paeonol significantly inhibited the proliferation of HCT116 cells in a dose- and time-dependent manner. | Int J Mol Med. 2020 Aug;46(2):675-684. | 
| SKOV3 cells | 1.2 mM | 24 and 48 hours | To evaluate the inhibitory effect of Paeonol on cell proliferation, results showed that Paeonol significantly inhibited the proliferation of SKOV3 cells. | Cell Death Dis. 2019 Aug 13;10(8):609. | 
| A2780 cells | 1.2 mM | 24 and 48 hours | To evaluate the inhibitory effect of Paeonol on cell proliferation, results showed that Paeonol significantly inhibited the proliferation of A2780 cells. | Cell Death Dis. 2019 Aug 13;10(8):609. | 
| NSC-34/hSOD1G93A (MT) | 100 µM | 24 hours | Evaluate the protective effect of Paeonol against glutamate, LPS, and H2O2-induced cytotoxicity, results showed Paeonol significantly improved cell viability | Antioxidants (Basel). 2022 Jul 18;11(7):1392. | 
| NSC-34/hSOD1WT (WT) | 100 µM | 24 hours | Evaluate the protective effect of Paeonol against glutamate, LPS, and H2O2-induced cytotoxicity, results showed Paeonol significantly improved cell viability | Antioxidants (Basel). 2022 Jul 18;11(7):1392. | 
| Cardiomyocytes | 50 µM | 24 hours | Paeonol promotes Mfn2-mediated mitochondrial fusion, restores mitochondrial function and cell viability, and inhibits Dox-induced cardiomyocyte apoptosis and oxidative stress. | J Adv Res. 2023 May;47:151-162. | 
| Primary microglial cells | 0.5 to 1 mM | 24 hours | Paeonol inhibited lipopolysaccharide-induced nitrite release and reduced the secretion of tumor necrosis factor-alpha and interleukin-1β. | Neural Regen Res. 2013 Jun 25;8(18):1637-43. | 
| RAW 264.7 cells | 25, 50 µM | 24 hours | Evaluate the effect of paeonol on LPS-induced MAPK protein expression in RAW 264.7 cells. Results showed that paeonol significantly reduced the protein expression levels of COX-2 and NF-κB and affected the phosphorylation of p-p38. | Biomolecules. 2022 Nov 3;12(11):1634. | 
| RAW 264.7 cells | 6.3, 12.5, 25, 50 µM | 24 hours | Evaluate the effect of paeonol on LPS-induced IL-6 and TNF-α production in RAW 264.7 cells. Results showed that paeonol inhibited the release of IL-6 and TNF-α in a concentration-dependent manner. | Biomolecules. 2022 Nov 3;12(11):1634. | 
| GMI-R1 cells | 4 µM | 24 hours | Paeonol promotes the transformation of LPS-treated GMI-R1 microglia from the M1 phenotype to the M2 phenotype. | CNS Neurosci Ther. 2023 Sep;29(9):2666-2679. | 
| Human primary umbilical vein endothelial cell (HUVEC) | 10 µM | 24 hours | To evaluate the effect of Paeonol on HUVEC cell viability, results showed that Paeonol treatment significantly enhanced HUVEC viability. | Drug Des Devel Ther. 2023 May 24;17:1567-1582. | 
| Aspergillus flavus | 0.625 mg/mL | 24 hours | Paeonol significantly destroyed both the outer amorphous layer and the inner fibrous layer of A. flavus cell walls, leading to thinner cell walls and chaotic cytoplasm. | Foods. 2021 Dec 1;10(12):2951. | 
| Human umbilical vein/vascular endothelial cell line (HUVEC-C) | 10 µM | 24 hours, 48 hours, 72 hours | To evaluate the effect of Paeonol on HUVEC-C cell numbers, results showed that Paeonol treatment significantly increased cell numbers. | Drug Des Devel Ther. 2023 May 24;17:1567-1582. | 
| RAW264.7 macrophages | 32, 64, 128 µg/mL | 3 hours pretreatment or 4 hours treatment | To assess the anti-infection activity and mechanism of paeonol against P. aeruginosa infection in vitro, results showed paeonol downregulated the expression of QS-related virulence genes and reduced PAO1-induced cell damage | Front Immunol. 2022 May 24;13:896874. | 
| BV-2 microglial cells | 10 or 30 µM | 30 min pretreatment followed by 24 hours stimulation | To investigate the effects of Paeonol on ATP-induced cell migratory activity. Results showed that Paeonol effectively reduced ATP-enhanced migratory activity. | Int J Mol Sci. 2015 Apr 21;16(4):8844-60. | 
| BV-2 microglial cells | 3, 10, or 30 µM | 30 min pretreatment followed by 24 hours stimulation | To investigate the inhibitory effects of Paeonol on LPS/IFN-γ-induced inflammatory responses. Results showed that Paeonol significantly inhibited the release of NO and the expressions of iNOS and COX-2. | Int J Mol Sci. 2015 Apr 21;16(4):8844-60. | 
| Primary cardiomyocytes | 25, 50, 100, 200 µM | 48 hours | To evaluate the effects of Paeonol on mitochondrial fusion and function in high glucose-treated cardiomyocytes. Results showed that 100 μmol/L Paeonol significantly increased mitochondrial volume, decreased mitochondrial number, inhibited mitochondrial oxidative stress, and improved ATP production and mitochondrial respiratory capacity. | Redox Biol. 2021 Oct;46:102098. | 
| SW1353 cells | 3, 10, 30 µM | 48 hours | Evaluate the effect of Paeonol on the viability of SW1353 cells, showing no effect on cell viability at 3–30 μM | Int J Mol Sci. 2014 Jul 2;15(7):11760-72. | 
| JJ012 cells | 3, 10, 30 µM | 48 hours | Evaluate the effect of Paeonol on the viability of JJ012 cells, showing no effect on cell viability at 3–30 μM | Int J Mol Sci. 2014 Jul 2;15(7):11760-72. | 
| NSC-34/hSOD1G93A (MT) | 347 nM | 5 min | Evaluate the uptake characteristics of [3H]Paeonol, results showed time-, concentration-, and pH-dependent uptake | Antioxidants (Basel). 2022 Jul 18;11(7):1392. | 
| NSC-34/hSOD1WT (WT) | 347 nM | 5 min | Evaluate the uptake characteristics of [3H]Paeonol, results showed time-, concentration-, and pH-dependent uptake | Antioxidants (Basel). 2022 Jul 18;11(7):1392. | 
| RAW 264.7 cells | 6.3, 12.5, 25, 50 µM | 6 hours | Evaluate the effect of paeonol on LPS-induced mRNA expression of IL-6, IL-1β, and TNF-α in RAW 264.7 cells. Results showed that paeonol reduced the mRNA expression levels of these inflammatory cytokines in a concentration-dependent manner. | Biomolecules. 2022 Nov 3;12(11):1634. | 
| Organotypic hippocampal slice cultures | 0.5 and 1 mM | 72 hours | Paeonol pretreatment markedly blocked lipopolysaccharide-induced hippocampal cell death and inhibited the release of nitrite and interleukin-1beta. | Neural Regen Res. 2013 Jun 25;8(18):1637-43. | 
| 3T3-L1 cells | 1000 µM | 8 days | Paeonol inhibits the differentiation of 3T3-L1 cells into mature adipocytes and reduces lipid accumulation. | Nutrients. 2020 Jan 24;12(2):309. | 
| Administration | Dosage | Frequency | Description | References | ||
| ICR mice | LPS-induced neuroinflammation model | Intraperitoneal injection | 10 or 30 mg/kg | Once daily for three consecutive days, followed by a single LPS injection | To investigate the effects of Paeonol on LPS-induced motor coordination dysfunction and microglial activation. Results showed that Paeonol significantly improved motor coordination in LPS-injected mice and reduced microglial activation. | Int J Mol Sci. 2015 Apr 21;16(4):8844-60. | 
| Sprague-Dawley rats | Chronic constrictive injury (CCI) model | Intragastric administration | 100 mg/kg | Twice daily for 21 days | Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway. | CNS Neurosci Ther. 2023 Sep;29(9):2666-2679. | 
| Wistar rats | Hepatic ischemia/reperfusion injury model | Oral | 100 mg/kg | Once daily for 7 days | To evaluate the protective effect of paeonol against hepatic ischemia/reperfusion injury, results showed that paeonol attenuated liver injury by inhibiting oxidative stress, inflammation, and apoptosis. | Antioxidants (Basel). 2022 Aug 29;11(9):1687 | 
| Sprague-Dawley rats | Dox-induced cardiotoxicity model | Oral gavage | 150 mg/kg | Once daily for two weeks | Paeonol activates the PKCε-Stat3-Mfn2 signaling pathway to promote mitochondrial fusion, alleviating Dox-induced cardiotoxicity and myocardial injury. | J Adv Res. 2023 May;47:151-162. | 
| BALB/c mice | IMQ-induced psoriasis-like skin inflammation model | Oral | 20 mg/kg and 40 mg/kg | Once daily for 7 days | To evaluate the therapeutic effect of compound B12 on IMQ-induced psoriasis-like skin inflammation. Results showed that compound B12 significantly alleviated skin inflammation symptoms and PASI score. | J Orthop Translat. 2024 Nov 24;50:1-13 | 
| BALB/c mice | IMQ-induced psoriasis-like skin inflammation model | Oral | 20 mg/kg and 40 mg/kg | Once daily for 7 days | To evaluate the therapeutic effect of compound B12 on IMQ-induced psoriasis-like skin inflammation. Results showed that compound B12 significantly alleviated skin inflammation symptoms and PASI score. | J Enzyme Inhib Med Chem. 2022 Dec;37(1):817-831 | 
| SPF mice | PAO1 acute infection model | Intragastric administration | 25, 50, 100 mg/kg | 3 consecutive days | To evaluate the anti-infection activity of paeonol in vivo, results showed paeonol decreased the bacterial load in the lung and inhibited the mRNA expression of inflammation cytokines | Front Immunol. 2022 May 24;13:896874. | 
| BALB/c mice | Lincomycin-induced antibiotic-associated diarrhea model | Oral | 25, 50, 100 mg/kg | Twice daily for 7 days | Evaluate the effect of paeonol on lincomycin-induced diarrhea in mice. Results showed that paeonol significantly improved diarrhea symptoms, reduced weight loss and water intake, and decreased serum levels of TNF-α and IL-4. | Biomolecules. 2022 Nov 3;12(11):1634. | 
| ApoE−/− mice | Murine carotid artery catheter guide wires injury model | Intraperitoneal injection | 30 mg/kg | Pretreated for 7 consecutive days, continued treatment after surgery until tissue collection | To evaluate the effect of Paeonol on vascular stenosis after vascular injury, results showed that Paeonol treatment significantly suppressed vascular neointima formation. | Drug Des Devel Ther. 2023 May 24;17:1567-1582. | 
| BALB/c nude mice | A2780 xenograft model | Intraperitoneal injection | 40 mg/kg | Once every 2 days, total of 6 times (12 days) | To evaluate the antitumor activity of Paeonol in vivo, results showed that Paeonol significantly inhibited tumor growth, and the effect was enhanced when combined with the autophagy inhibitor HCQ. | Cell Death Dis. 2019 Aug 13;10(8):609. | 
| Sprague-Dawley rats | Diabetic cardiomyopathy model | Oral gavage | 75, 150, 300 mg/kg | Once daily for 12 weeks | To evaluate the protective effects of Paeonol on diabetic cardiomyopathy. Results showed that Paeonol (150 or 300 mg/kg/day) significantly improved cardiac function, reduced myocardial hypertrophy and fibrosis, inhibited cardiomyocyte apoptosis and oxidative stress, and promoted mitochondrial fusion and functional recovery. | Redox Biol. 2021 Oct;46:102098. | 
| Dose | Mice: 20 mg/kg[3] (i.p.); 20 mg/kg - 80 mg/kg[4] (p.o.) Rat: 2.5 mg/kg - 10 mg/kg[5] (i.v.); 30 mg/kg - 100 mg/kg[2] (i.p.); 100 mg/kg, 200 mg/kg[6] (p.o.) | ||||||||||||||||||||||
| Administration | i.p., p.o., i.v. | ||||||||||||||||||||||
| Pharmacokinetics | 
 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 6.02mL 1.20mL 0.60mL | 30.09mL 6.02mL 3.01mL | 60.18mL 12.04mL 6.02mL | |
| CAS号 | 552-41-0 | 
| 分子式 | C9H10O3 | 
| 分子量 | 166.17 | 
| SMILES Code | CC(C1=CC=C(OC)C=C1O)=O | 
| MDL No. | MFCD00008730 | 
| 别名 | 2-羟基-4-甲氧基苯乙酮 ;2'-Hydroxy-4'-methoxyacetophenone; Peonol; NSC 401442 | 
| 运输 | 蓝冰 | 
| InChI Key | UILPJVPSNHJFIK-UHFFFAOYSA-N | 
| Pubchem ID | 11092 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C | 
| 溶解方案 | DMSO: 40 mg/mL(240.71 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 1 mg/mL(6.02 mM),配合低频超声助溶 无水乙醇: 45 mg/mL(270.8 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1